Impel Pharmaceuticals Inc. (IMPL) Misses Q2 EPS by 31c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Impel Neuropharma (IMPL) PT Lowered to $40 at Cowen
November 14, 2022 10:41 AM ESTCowen analyst Ken Cacciatore lowered the price target on Impel Neuropharma (NASDAQ: IMPL) to $40.00 (from $55.00) while maintaining a Outperform rating.
The analyst commented, "Trudhesa's launch metrics continue to make progress and match the consistent positive clinician feedback as a rescue medication in... More
